Will This Analyst Downgrade Hurt Clovis Oncology (CLVS) Stock Today? (Update)

Update (9:35 a.m.): Updated with Tuesday market open information.

NEW YORK (TheStreet) -- Citigroup downgraded Clovis Oncology  (CLVS) to "neutral" and set a $53 price target. The firm notes the company could face increased competition from AstraZeneca (AZN).

The stock was down 12.57% to $41.75 at 9:33 a.m. on Tuesday.

Must Read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

CLVS Chart

CLVS data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

This Will Be the Ultimate Buy (or Sell) Signal for Stocks

This Will Be the Ultimate Buy (or Sell) Signal for Stocks

Shares of Square Slip After Venmo Debit Card Announcement

Shares of Square Slip After Venmo Debit Card Announcement

3 Fierce Chinese Tech Stocks to Gamble on Right Now

3 Fierce Chinese Tech Stocks to Gamble on Right Now

Stocks Slammed on Latest Trump Tariff Fears

Stocks Slammed on Latest Trump Tariff Fears

Boeing Slides as China Premier Li Says Willing to Continue Talks With Airbus

Boeing Slides as China Premier Li Says Willing to Continue Talks With Airbus